Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside
Metrics: PDF 2264 views | HTML 3127 views | ?
Jingjing Wu1, Mingzhi Zhang1 and Delong Liu1
1 Department of Oncology, The first Affiliated Hospital of Zhengzhou University, Zhengzhou, China
Delong Liu, email:
Keywords: Bruton tyrosine kinase, ONO/GS-4059, ibrutinib
Received: September 20, 2016 Accepted: October 10, 2016 Published: October 20, 2016
The Bruton tyrosine kinase (BTK) inhibitor, ibrutinib, has been approved for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom’s macroglobulinemia. Acquired resistance to ibrutinib due to BTK C481S mutation has been reported. Mutations in PLCγ2 can also mediate resistance to ibrutinib. Untoward effects due to off-target effects are also disadvantages of ibrutinib. More selective and potent BTK inhibitors (ACP-196, ONO/GS-4059, BGB-3111, CC-292) are being investigated. This review summarized the preclinical research and clinical data of ONO/GS-4059.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.